Exclusive Content
China Adds Semaglutide, Cancer Drugs to Essential Medicines List
China updated its National Essential Medicines List for the first time in 8 years, adding semaglutide and cancer drugs. Here's what it means for foreign pharma market access in 2026.
Joint Venture Setup China 2026: 6-Step Structure Guide
Structure your China joint venture in 2026 with this 6-step guide. Covers equity splits, capital schedules, IP protection, and exit planning with real cost data.
China Market Entry Timeline Estimator: Build a Dependency-Based Launch Plan
Plan your China entity registration with this 6-phase timeline estimator. From pre-entry planning to go-live in 19-35 weeks. Includes city-specific adjustments.
China Market Entry Regulatory Reference: Core Laws and Agencies
A complete China market entry regulatory reference covering 5 core statutes, 7 key government agencies, and a 7-step compliance checklist for foreign investors in 2026.
China City Incentives in 2026: How Foreign Investors Should Verify Grants and Tax Claims
23 Chinese tier-2 cities launched 2026 FDI incentive programs with tax rebates up to 15% and cash grants reaching 50M RMB. See the top 5 city packages compared.
China IP Enforcement in 2026: Punitive Damages and Evidence Planning for Foreign Rights Holders
China's 2026 IP protection measures raise punitive damage caps to 5× actual losses. Learn how 35 specialized IP courts and the new Shanghai litigation fund benefit foreign firms.